Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Octreotide Acetate

FDA-approved product (injectable, injection), marketed as Bynfezia Pen, Mycapssa, Octreotide Acetate and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Octreotide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acromegaly
  • Carcinoid tumor
  • Metastasis
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Somatostatin and analogues
FDA pharmacologic class
Somatostatin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Octreotide Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Octreotide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study

    NCT02147470 · start 2013-02

    Registered record
    Registry ID
    NCT02147470
    Conditions
    Liver Cirrhosis and Acute Kidney Injury
    Interventions
    Definity ultrasound contrast agent
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2013-02
    Completion
    Not recorded
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis and Acute Kidney Injury
    InterventionDefinity ultrasound contrast agent
    PhaseNot applicable
    Registry statusUnknown

  • Acromegaly Combination Treatment Study

    NCT01538966 · start 2012-03-29

    Registered record
    Registry ID
    NCT01538966
    Conditions
    Acromegaly
    Interventions
    Pegvisomant; Octreotide LAR; Lanreotide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2012-03-29
    Completion
    2022-05-20
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionPegvisomant; Octreotide LAR; Lanreotide
    PhaseNot applicable
    Registry statusTerminated

  • Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

    NCT01412424 · start 2012-03

    Registered record
    Registry ID
    NCT01412424
    Conditions
    Acromegaly
    Interventions
    Octreotide capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-03
    Completion
    2014-05
    Enrolment
    155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionOctreotide capsules
    PhasePhase 3
    Registry statusCompleted

  • IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC

    NCT01480986 · start 2011-09

    Registered record
    Registry ID
    NCT01480986
    Conditions
    Progression Free Survival of the Treatment
    Interventions
    Irinotecan combined with cisplatin, octreotide lar
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-09
    Completion
    2013-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProgression Free Survival of the Treatment
    InterventionIrinotecan combined with cisplatin, octreotide lar
    PhasePhase 2
    Registry statusCompleted

  • Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency

    NCT01377246 · start 2011-05

    Registered record
    Registry ID
    NCT01377246
    Conditions
    Autosomal Dominant Polycystic Kidney Disease
    Interventions
    Octreotide-LAR; Saline solution.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-05
    Completion
    2017-10-18
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutosomal Dominant Polycystic Kidney Disease
    InterventionOctreotide-LAR; Saline solution.
    PhasePhase 3
    Registry statusCompleted

  • Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

    NCT01229943 · start 2010-10-15

    Registered record
    Registry ID
    NCT01229943
    Conditions
    Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Pancreatic Neuroendocrine Tumor; Pancreatic Gastrinoma; Pancreatic Neuroendocrine Tumor G1; Pancreatic Neuroendocrine Tumor G2; Pancreatic Vipoma
    Interventions
    Bevacizumab; Everolimus; Octreotide Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-10-15
    Completion
    2018-01-03
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Pancreatic Neuroendocrine Tumor; Locally Advanced Pancreatic Neuroendocrine Tumor; Pancreatic Gastrinoma; Pancreatic Neuroendocrine Tumor G1 +2 more
    InterventionBevacizumab; Everolimus; Octreotide Acetate
    PhasePhase 2
    Registry statusCompleted

  • Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

    NCT01121939 · start 2010-05

    Registered record
    Registry ID
    NCT01121939
    Conditions
    Neuroendocrine Carcinoma
    Interventions
    Bevacizumab; Pertuzumab; Sandostatin LAR® Depot
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-05
    Completion
    2015-08
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Carcinoma
    InterventionBevacizumab; Pertuzumab; Sandostatin LAR® Depot
    PhasePhase 2
    Registry statusCompleted

  • AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

    NCT00427349 · start 2008-11-07

    Registered record
    Registry ID
    NCT00427349
    Conditions
    Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
    Interventions
    AMG 706; octreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11-07
    Completion
    2015-04
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
    InterventionAMG 706; octreotide
    PhasePhase 2
    Registry statusCompleted

  • Acute Application of Pegvisomant and Octreotide in Acromegaly

    NCT00595140 · start 2008-01

    Registered record
    Registry ID
    NCT00595140
    Conditions
    Acromegaly
    Interventions
    pegvisomant; combination with somatostatin analogue octreotide; combination with dopamine agonist cabergoline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-03
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    Interventionpegvisomant; combination with somatostatin analogue octreotide; combination with dopamine agonist cabergoline
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

    NCT00332969 · start 2005-09

    Registered record
    Registry ID
    NCT00332969
    Conditions
    Thymoma
    Interventions
    Octreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-09
    Completion
    Not recorded
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThymoma
    InterventionOctreotide
    PhasePhase 2
    Registry statusCompleted

  • Ghrelin Suppression by Octreotide in Prader-Willi

    NCT01613495 · start 2005-08

    Registered record
    Registry ID
    NCT01613495
    Conditions
    Prader Willis Syndrome
    Interventions
    Placebo; Octreotide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2005-08
    Completion
    2024-11
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrader Willis Syndrome
    InterventionPlacebo; Octreotide
    PhaseNot applicable
    Registry statusUnknown

  • Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

    NCT00444873 · start 2005-01

    Registered record
    Registry ID
    NCT00444873
    Conditions
    Acromegaly
    Interventions
    lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-01
    Completion
    2008-01
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    Interventionlanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
    PhasePhase 3
    Registry statusCompleted

  • The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed

    NCT00534677 · start 2004-05

    Registered record
    Registry ID
    NCT00534677
    Conditions
    Portal Hypertension; Cirrhosis; Hematemesis; Melena
    Interventions
    Terlipressin; Octreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-05
    Completion
    2005-07
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPortal Hypertension; Cirrhosis; Hematemesis; Melena
    InterventionTerlipressin; Octreotide
    PhasePhase 4
    Registry statusCompleted

  • Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.

    NCT00170742 · start 2003-12

    Registered record
    Registry ID
    NCT00170742
    Conditions
    Proliferative Diabetic Retinopathy
    Interventions
    Octreotide, 30 mg i.m. LAR formulation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2003-12
    Completion
    Not recorded
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProliferative Diabetic Retinopathy
    InterventionOctreotide, 30 mg i.m. LAR formulation
    PhasePhase 3
    Registry statusTerminated

  • Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity

    NCT00094146 · start 2002-01

    Registered record
    Registry ID
    NCT00094146
    Conditions
    Primary Insulin Hypersecretion; Obesity
    Interventions
    Sandostatin LAR Depot
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-01
    Completion
    2002-12
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Insulin Hypersecretion; Obesity
    InterventionSandostatin LAR Depot
    PhasePhase 2
    Registry statusCompleted